Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025 [Forbes]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Forbes
In this photo is a Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (Photographer: Shelby Knowles/Bloomberg) © 2024 Bloomberg Finance LP The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers, employers and government health programs who cover it in 2025. Already, weight loss prescriptions Wegovy, Rybelsus and Saxenda—along with Ozempic—are the “single biggest driver” of employer health costs, adding 1% to the total premium expense for 2025, data released last fall from the benefits consultancy Aon said. These GLP-1 drugs are adding to general healthcare inflation that is projected to increase employer-sponsored health insurance coverage by 9%, eclipsing $16,000 per employee in 2025. The spike in premiums, which is higher than the 6.4% increase employers faced this year and in 2023, comes before any “cost savings strategies” are implemented, Aon said. But a new r
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer [Yahoo! Finance]Yahoo! Finance
- Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst [Yahoo! Finance]Yahoo! Finance
- Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them [Yahoo! Finance]Yahoo! Finance
- Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver [Forbes]Forbes
- Eli Lilly and Company (NYSE: LLY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website